Iclaprim - Motif Bio

Drug Profile

Iclaprim - Motif Bio

Alternative Names: AR-100; MTF-100; Ro-48-2622

Latest Information Update: 15 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Arpida; Evolva Holding SA; Motif Bio
  • Class Antibacterials; Pyrimidines; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Methicillin-resistant Staphylococcus aureus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Skin and soft tissue infections
  • Phase II Nosocomial pneumonia
  • Phase I Nosocomial infections
  • Preclinical Methicillin-resistant Staphylococcus aureus infections
  • Discontinued Chlamydial infections; Gonorrhoea

Most Recent Events

  • 14 Jun 2018 Motif Bio completes rolling submission of NDA for iclaprim in Skin-and-soft-tissue-infections (IV)
  • 11 Jun 2018 Pooled adverse events data and efficacy data from phase III REVIVE-1 and REVIVE-2 trials in Skin and soft tissue infections presented at the American Society of Microbiology Microbe Meeting (ASSM-2018)
  • 11 Jun 2018 Motif Bio completes a phase II trial in Nosocomial pneumonia in Estonia, Latvia and Lithuania, Russia (IV) (NCT00543608)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top